First patient dosed in Advaxis’ phase III cervical cancer trial
A phase III trial testing the ability of Advaxis Inc.’s lead immunotherapy candidate, axalimogene filolisbac, to improve disease-free survival among patients with high-risk locally advanced cervical cancer has enrolled and dosed its first patient. The FDA fast-tracked study, called AIM2CERV, is expected to enroll 450 patients and is being run under a special protocol assessment.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST